Study Subjects
The Northwestern Medicine Enterprise Data Warehouse was queried to
identify all patients who were prescribed ibrutinib between July 2012
and July 2016, and received primary oncologic care at our institution.
Patients were aged 18 to 90 years old, and all patients with a prior
history of AF were excluded. One hundred sixty-nine patients were
initially identified. Of these patients, those who had a transthoracic
echocardiogram prior to initiation of ibrutinib therapy were included,
yielding a total 75 patients. Nine patients were excluded because
echocardiographic images were not available for review on Northwestern
software, yielding a total 66 patients.
Demographic information was collected through a retrospective chart
review of each patient’s electronic medical record, including gender,
race, age of patient at initiation of ibrutinib, and body mass index
(BMI). Comorbidities included hypertension (HTN), hyperlipidemia (HLD),
diabetes (DM), coronary artery disease (CAD) and clinical history of
heart failure (HF) prior to initiation of ibrutinib. Information
regarding ibrutinib dose, length of follow up, rates of CVA among
patients who developed IRAF and rates of anticoagulant and antiplatelet
use for patients with IRAF were also noted. Duration of follow up was
defined as either time to development of AF, time until last follow up,
or time until patient death. The Northwestern University institutional
review board approved this study.